← SynDRA

VENETOCLAX

SynDRA canonical compound SYN0037841 — structure-anchored drug synonym record

All known targets

• BCL2
• BCL2L1
• BCL2L2
• ASPH
• BAD
• MCL1

Mechanisms of action (all sources)

• BCL2 inhibitor
• Apoptosis regulator Bcl-2 inhibitor
• BCL2 ANTAGONIST
• BCL2L1 ANTAGONIST
• BCL2L2 ANTAGONIST
• MCL1 ANTAGONIST
• BCL inhibitor

Drug classes

• Antineoplastic Agents
• P-Glycoprotein Inhibitors
• BCL-2 Inhibitor

ATC classes

• L01X · OTHER ANTINEOPLASTIC AGENTS

Cross-references

• PubChem CID: 49846579
• ChEMBL: CHEMBL3137309
• DrugBank: DB11581
• ChEBI: CHEBI:133021
• KEGG: D10679
• RxNorm: 1747556
• PDB: LBM
• Wikipedia: Venetoclax
• LINCS BRD: BRD-K62391742

Synonyms

• venclyxto
• ABT-199
• venclexta
• GDC-0199
• ABT199
• ABBVIE
• C45H50CLN7O7S
• CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY
• RG-7601
• RG7601
• UNII-N54AIC43PW
• Venclexta
• Venclyxto
• VENETOCLAX (ABT-199)
• ABT 199
• GDC 0199
• Venetoclax (ABT199)
• Venetoclax; Abt-199
• Venetoclax(ABT-199)
• 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
• Venetoclax (ABT-199)
• N54AIC43PW
• ABT-199 (GDC-0199)
• 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy
• 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
• benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-
• BDBM189459
• 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide
• 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
• 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
• Venetoclax [USAN:INN]
• Venclexta (TN)
• Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-
• VENETOCLAX [MI]
• VENETOCLAX [INN]
• VENETOCLAX [JAN]
• VENETOCLAX [USAN]
• VENETOCLAX [WHO-DD]

Reported adverse events

• Abdominal pain
• Arthralgia
• Blood creatinine increased
• Constipation
• Dizziness
• Fatigue
• Febrile neutropenia
• Headache
• Hypotension
• Infection
• Nausea
• Neutropenia